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aFIhe National Heart, Lung, and Blood Institute (NHLBI)
trategic Plan describes an ambitious agenda in cardiovas-
ular disease research, with most of it implemented via
rants and contracts to extramural scientists. There are over
5 NHLBI program scientists, who work to initiate, cata-
yze, evaluate, and oversee cardiovascular research efforts.
hese scientists are divided into 8 branches within an
verarching Division of Cardiovascular Sciences (DCVS).
he DCVS represents the union of 2 previously existing
ivisions, the Division of Cardiovascular Disease and the
ivision of Prevention and Population Sciences; both divi-
ions recently prepared detailed strategic plans (1,2).
DCVS provides leadership and supports basic, clinical,
opulation, and health services research on the causes,
revention, and treatment of cardiovascular diseases. The
ivision fosters research in disease areas, such as athero-
hrombosis, heart attack and heart failure, high blood
ressure, stroke, atrial and ventricular arrhythmias, sudden
ardiac death, adult and pediatric congenital heart disease,
ardiovascular complications of diabetes and obesity, and
ther cardiovascular disorders. Research also includes a
umber of well-known epidemiological cohort studies that
escribe disease and risk factor patterns in populations;
linical trials of interventions to prevent disease and to
revent or modulate risk factors; studies of genetic, behav-
oral, sociocultural, health systems, and environmental in-
uences on disease risk and outcomes; and studies of the
pplication of prevention and treatment strategies to deter-
ine how to improve clinical care and public health. The
rom the Division of Cardiovascular Sciences, National Heart, Lung, and Bloodi
nstitute, Bethesda, Maryland.
Manuscript received January 15, 2009; accepted April 13, 2009.ivision supports training and career development for these
reas of research.
DCVS is organized operationally into 8 scientific
ranches, a career development office, and an Office of
iostatistics Research.
dvanced Technologies and Surgery Branch
his branch conducts and manages an integrated basic and
linical research program to study innovative and developing
echnologies for the diagnosis, prevention, and treatment of
ardiovascular disease. The branch is also a focal point for
ardiovascular device development, and is currently funding
evelopmental research of ventricular assist devices for the
ediatric population. Other important areas that the branch
versees include dedicated programs in nanotechnology,
ystems biology, and progenitor cells. See Table 1 for
pecific examples of major programs.
therothrombosis and
oronary Artery Disease Branch
his branch conducts and manages an integrated basic and
linical research program to study the etiology, pathogene-
is, prevention, diagnosis, and treatment of coronary artery
isease and atherothrombosis. The branch’s portfolio in-
ludes funded studies related to the entire spectrum of the
therothrombotic process. The branch is also engaged in a
eries of clinical trials related to coronary disease and
therothrombosis. Examples of 3 major trials are provided
n Table 1.
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tructural Disease Branch
his branch conducts and manages an integrated basic and
able 1 Examples of Major Initiatives of NHLBI Cardiovascular Bra
ATSB Ongoing INTERMACS—a national audited registry for patients who are
heart failure.
New CCTRN—to accelerate clinical research in the evaluation of novel
New CTSN—to evaluate surgical and minimally invasive interventional
Anticipated NHLBI Progenitor Cell Biology Consortium—to develop bet
anticipated later in 2009.
ACAD Ongoing FREEDOM—clinical trial to assess the optimal revascularizati
Ongoing BARI 2D—clinical trial to examine initial medical versus initia
New COAG—clinical trial of using genetic markers to guide warfarin d
HDSDB Ongoing Marfan trial—trial of beta-blocker therapy (atenolol) vs. angio
syndrome—evaluates rates of change in aortic growth and aortic re
Ongoing SVR—trial of right ventricular vs. modified Blalock-Taussig sh
Network’s first randomized surgical trial in infants undergoing the N
New An important initiative was launched in 2008, the Children and C
educate parents and the public about the challenges and rewards o
as parents, children, and pediatric researchers discuss their experie
HFAB Ongoing TOPCAT—clinical trial to test the roles of aldosterone antagon
Ongoing STICH—clinical trial of surgical revascularization or ventricula
Ongoing IMMEDIATE—clinical trial of pre-hospital administration of glu
Ongoing PREDICTS—trial to test the effectiveness of a wearable nonin
New CABANA—support of the CABANA trial in 2009, to test the treatm
pharmacologic therapy for either rate or rhythm control.
VBHAB Ongoing CORAL—to test medical therapy with stenting vs. medical the
Ongoing CLEVER—to test optimal medical care alone or plus stent or
New A translational program on “Mechanisms and Management of Ca
the underlying mechanisms of metabolic and anthropometric abno
relationship to cardiovascular disease risk.
CAPB Ongoing ACCORD—1 of 3 trials demonstrated that aggressive manage
events; trials of lipid-lowering and aggressive blood pressure contro
Recently completed HF-ACTION—demonstrated that formal exercise tr
heart failure.
Recently completed WLM—demonstrated that certain strategies may
obese adults.
Anticipated SPRINT—a trial that will randomize patients with hyperten
EB Ongoing Framingham Heart Study—a large, longitudinal, 3-generation
Ongoing CARDIA—a large longitudinal study of young African-America
cardiovascular disease.
Ongoing ARIC—a large longitudinal study of men and women age 45
component.
Ongoing CHS—a large longitudinal cohort study of persons age 65 yea
in the elderly.
Ongoing MESA—a large longitudinal study of men and women age 45
cardiovascular disease.
New HCHS/SOL—a large longitudinal cohort study of Hispanics of 4 d
cardiovascular disease risk.
WHIB Ongoing A series of contracts was awarded in 2007 to fund new studi
and investigate the impact of genetic and biological markers on co
New Genome-wide scans and phenotype data from WHI data are bein
SHARe programs (SNPs and Health Association Resource).
CAD Atherothrombosis and Coronary Artery Disease Branch; ACCORD Action to Control Card
n Communities study; ATSB  Advanced Technologies and Surgery Branch; BARI 2D  Bypass
Ntiarrhythmic Drug Therapy for Atrial Fibrillation; CAPB  Clinical Applications and Prevention Br
herapy Research Network; CHS  Cardiovascular Health Study; CLEVER  Claudication: Exercise
ORAL  Cardiovascular Outcomes in Renal Atherosclerotic Lesions; CTSN  Cardiothoracic Su
evascularization Evaluation in Patients With Diabetes Mellitus: Optional Management of Mul
evelopment and Structural Heart Disease Branch; HFAB Heart Failure and Arrhythmias Branch;
mmunodeficiency virus; IMMEDIATE  Immediate Myocardial Metabolic Enhancement During Init
ssisted Circulatory Support; MESAMulti-Ethnic Study of Atherosclerosis; NHLBI National Hea
tudies; SHARe  SNPs and Health Association Resource project; SNP  single nucleotide polym
eart Failure Hypothesis 2; SVR  Single Ventricle Reconstruction Study; TOPCAT  Trial of Aldost
ascular Biology, Hypertension, and Atherothrombosis Branch; WHI  Women’s Health Initiative;linical research program to study heart development, con- aenital heart disease, and valvular heart disease. The Pedi-
tric Heart Network (3) provides an effective, flexible
nfrastructure to study congenital heart disease in children
s
ing FDA-approved mechanical circulatory support device therapy to treat advanced
erapy treatment strategies.
gies.
erstanding of stem and progenitor cell biology and uses of the cells. Funding is
tegy in diabetics.
cularization treatment of diabetics.
II receptor blocker therapy (losartan) in individuals with Marfan
ation in individuals 6 months old to 26 years of age.
infants with single ventricle defect undergoing staged reconstruction is the
d procedure.
Studies website (www.ChildrenandClinicalStudies.nhlbi.nih.gov), designed to
atric research participation. This award-winning site offers visitors an “inside view”
n research.
patients with heart failure with preserved ejection fraction.
ration in heart failure with decreased ejection fraction.
nsulin-potassium in patients with acute coronary syndromes.
defibrillator.
rategy of catheter ablation for atrial fibrillation against current state-of-the-art
lone in patients with significant renal artery stenosis and systolic hypertension.
pervised exercise in patients with PAD.
scular and Metabolic Complications of HIV/AIDS” was funded in 2008 to elucidate
es seen in HIV infection and highly active antiretroviral therapy and their
of type 2 diabetes did not result in a significant reduction of major cardiovascular
nue.
is safe and may result in modest improvements among patients with systolic
re effective than others for maintaining weight loss in overweight and
aggressive or standard degrees of systolic blood pressure control.
of adults that examines risk factors and progression of cardiovascular disease.
white men and women, followed since 1985 that examines predictors of adult
ears, followed since 1987 that also includes a community surveillance
older, followed since 1989 that evaluates determinants of cardiovascular risk
years from 4 ethnic groups, followed since 2000 that focuses on subclinical
t geographic origins, focusing on the association of acculturation with
elp explain the post-menopausal hormone therapy and other clinical trial findings
diseases affecting post-menopausal women.
d to the National Center for Bioinformatics for distribution through the NHLBI
lar Risk in Diabetes; AIDS  acquired immune deficiency syndrome; ARIC Atherosclerosis Risk
lasty Revascularization Investigation in Type 2 Diabetics; CABANA  Catheter ABlation Versus
ARDIA  Coronary Artery Risk Development in Young Adults study; CCTRN  Cardiovascular Cell
doluminal Revascularization; COAG  Clarification of Optimal Anticoagulation Through Genetics;
etwork; EB  Epidemiology Branch; FDA  Food and Drug Administration; FREEDOM  Future
Disease; HCHS/SOL  Hispanic Community Health Study/Study of Latinos; HDSDB  Heart
ION Heart Failure–A Controlled Trial Investigating Outcomes of Exercise Training; HIV human
ssment and Treatment in Emergency Care; INTERMACS  Interagency Registry for Mechanically
, and Blood Institute; PAD peripheral arterial disease; PREDICTS PREDiction of ICd Therapies
; SPRINT  Systolic Blood Pressure Intervention Trial; STICH  Surgical Treatments for Ischemic
ntagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure; VBHAB 
Women’s Health Initiative Branch; WLM  Weight Loss Maintenance.nche
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July 14, 2009:265–8 Extramural Division of Cardiovascular Sciences of the NHLBIardiovascular Translation Consortium will join the Pedi-
tric Heart Network. Details about these 2 programs will
ppear in future columns. This branch is also the focal point
or coordination of many activities related to pediatric
linical research within the NHLBI and the National
nstitutes of Health.
eart Failure and Arrhythmias Branch
his branch conducts and manages an integrated basic and
linical research program to study normal cardiac function
nd pathogenesis to improve diagnosis, treatment, and
revention of heart failure and arrhythmias. In 2007, the
eart Failure Network was initiated to accelerate research
n the diagnosis and management of heart failure and to
mprove outcomes through evaluation of novel therapies
nd optimal application of existing therapies. The branch is
lso responsible for overseeing resuscitation science through
upport of fundamental resuscitation research studies and
he Resuscitation Outcomes Consortium, which provides
upport for clinical trials in the areas of cardiopulmonary
rrest and severe traumatic injury. Other supported clinical
rials are shown in Table 1.
ascular Biology, Hypertension,
nd Atherothrombosis Branch
his branch conducts and manages an integrated basic and
linical extramural research program to investigate vascular
iology, and the etiology, pathogenesis, prevention, diagno-
is, and treatment of hypertension and vascular diseases.
hrough the Specialized Centers for Clinically Oriented
esearch in vascular injury, repair, and remodeling, the
ranch supports translational studies in vascular diseases,
ncluding aortic aneurysms, coronary artery disease, and
etabolic syndrome. In 2007, GenTAC (Genetically Trig-
ered Thoracic Aneurysms and Cardiovascular Conditions),
data and biospecimen registry, was established to provide
esources to the scientific community to advance the clinical
anagement of genetically triggered thoracic aortic aneu-
ysms. The branch also supports basic and translational
esearch on cardiovascular complications of human immu-
odeficiency virus/acquired immune deficiency syndrome.
pidemiology Branch
his branch oversees major population-based cohort studies
hat discover and describe major risk factors for cardiovas-
ular disease. Several examples are shown in Table 1. Some
ohort studies focus on specific demographic groups, such as
he Jackson Heart Study of African Americans and the
trong Heart Study of Native Americans. The Epidemiol-
gy Branch oversees a number of major efforts in genetic spidemiology, such as the Framingham SHARe (SNPs and
ealth Association Resource) project, CARe (Candidate
ene Association Resource), and STAMPEED (SNP
yping for Association with Multiple Phenotypes from
xisting Epidemiologic Data). The branch also partially
upports several Centers for Disease Control-based population-
ased survey studies, including the National Health and
utrition Examination Survey.
linical Applications and Prevention Branch
his branch primarily oversees interventional trials that are
imed at primary prevention of cardiovascular events or at
etter management of cardiovascular risk factors. Behavioral
edicine and the influence of psychosocial factors are major
reas of emphasis of many research efforts. Several major
tudies are shown in Table 1. In conjunction with the
pidemiology Branch, the branch is also interested in
ealth services research, and as part of this effort is oversee-
ng a major clinical epidemiology program that is based on
ich electronic medical record documentation of over 10
illion patients enrolled in a large Health Maintenance
rganization research network.
omen’s Health Initiative Branch
his branch oversees several major now-completed trials of
ormone therapy and other interventions for primary pre-
ention of chronic disease, as well as a parallel observational
tudy. At this time, over 100,000 older women continue to
e followed. Because of a rich bank of biological specimens,
ighly detailed baseline and follow-up data, and a large
umber of carefully adjudicated events, the Women’s
ealth Initiative studies continue to be a highly productive
ource of scientific effort. As an example of a major ongoing
roject, there are plans to obtain detailed genotype infor-
ation on over 10,000 African-American and Hispanic
omen.
ffice of Research Training
nd Career Development
his office supports research training and career develop-
ent programs for individuals at many educational levels,
rom high school to faculty, as well as training programs for
ndividuals from under-represented groups. Many of these
rograms are designed to take emerging and promising
cientific and technological advances from discovery
hrough pre-clinical and clinical studies. A K12 institutional
raining program, Research Career Development in Vascu-
ar Medicine, was established in 2007 to provide compre-
ensive clinical research training for physicians wanting to
pecialize in vascular medicine. The office also collaborates
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ions to ensure that training programs meet both the current
nd future needs of the cardiovascular research workforce.
ffice of Biostatistics Research
he statisticians in this office provide a valuable resource to
ll of the NHLBI and to the extramural scientific commu-
ity by their active involvement in the planning and execu-
ion of nearly all major NHLBI-supported projects, partic-
larly clinical trials, often from the point of conception. In
ddition, the office oversees its own active research agenda,
ith particular attention to statistical genetics and statistical
hallenges of modern-day clinical trials.
Although the NHLBI’s extramural cardiovascular pro-
ram staff is divided into multiple branches, we strive for a
orking atmosphere in which there is fully open commu-
ication among all program staff. Thus, it is quite common
hat staff from different branches work together on major
fforts, including large-scale multicenter clinical trials, re-
earch based on population-based cohort studies, researcholicies that are relevant throughout the Institute, and
onception and development of new ideas and initiatives. In
he same spirit, we recognize that we must not only all work
losely with one another, but also share this philosophy of open
ommunication with the extramural scientific community, as
e seek to foster the best scientific research needed to solve the
ublic health challenges we face.
eprint requests and correspondence: Dr. Michael S. Lauer,
ational Heart, Lung, and Blood Institute, 6701 Rockledge Drive,
oom 10122, Bethesda, Maryland 20892. E-mail: lauerm@
hlbi.nih.gov.
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